In the results from our ovarian cancer patients, among these markers, CD97, CD104, CD107a, and CD121a are significantly more expressed in the CD133 and CD44 double-positive ascites cells (Ascites_133+44+ cells) than in ovarian or metastatic tumors. This evidence concerns the gene CD44 and ovarian carcinoma.